Engineered T Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End-User, By Region and Competition, 2020-2030F

Description

Global Engineered T Cells Market for engineered T cells was valued at USD 26.31 billion in 2024 and is projected to reach USD 136.26 billion by 2030, expanding at a compound annual growth rate (CAGR) of 31.51% during the forecast period. This growth is primarily driven by rapid advancements in cellular immunotherapy and the increasing adoption of engineered T cell therapies in oncology.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 26.31 Billion
Market Size 2030	USD 136.26 Billion
CAGR 2025-2030	31.51%
Fastest Growing Segment	Cancer Research Centers
Largest Market	North America

Engineered T cell therapies-particularly Chimeric Antigen Receptor T cells (CAR-T) and T Cell Receptor T cells (TCR-T)-have transformed cancer treatment by leveraging the body's immune system to identify and destroy malignant cells. Ongoing progress in synthetic biology and gene editing has significantly improved the safety, efficacy, and persistence of these therapies, positioning them as a promising solution for both hematologic malignancies and solid tumors.

Regulatory agencies are accelerating the approval processes and broadening indications for these therapies, prompting substantial investments from biotechnology and pharmaceutical companies in research and development. These investments aim to optimize therapeutic design, enhance manufacturing efficiency, and expand the clinical applications of engineered T cells. Market growth is further supported by increasing patient awareness, higher healthcare spending, and strengthening collaborations between academic institutions and industry stakeholders to foster innovation.

Key Market Drivers

Advancements in Immunotherapy Research

Immunotherapy has emerged as a transformative approach in modern medicine, particularly in the treatment of cancer. Engineered T cell therapies, such as CAR-T and TCR-T, have gained significant traction due to their ability to utilize the immune system for targeted therapeutic interventions. These innovations stem from a deeper understanding of immune system mechanisms, enabling the development of highly specialized treatments.

For example, CAR-T cell therapy involves modifying a patient's own T cells to recognize and destroy cancer cells. Since the first CAR-T therapy received regulatory approval in 2017, over 30,000 patients with hematologic cancers have undergone treatment, with some achieving durable remissions lasting a decade or more.

Key Market Challenges

Manufacturing Complexity

The production of engineered T cell therapies is highly complex and requires rigorous quality control protocols. Ensuring T cell viability and functionality throughout the manufacturing process is essential for therapeutic success. Scaling up production to meet increasing demand poses significant challenges, as even minor variations in manufacturing conditions can affect product consistency and treatment outcomes.

Key Market Trends

Expansion into Solid Tumors

While CAR-T therapies have primarily been used to treat hematologic cancers, research is increasingly directed toward expanding their use in solid tumors. Emerging clinical trials are focused on overcoming the unique biological barriers presented by solid tumors, potentially broadening the therapeutic scope of engineered T cells and extending their benefits to a wider patient population.

Key Market Players

Amgen Inc
Athenex, Inc.
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
Eli Lilly & Co
Gilead Sciences Inc
Novartis AG
Oxford Biomedica PLC
Pfizer Inc
Precision BioSciences Inc

Report Scope:

In this report, the Global Engineered T Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Engineered T Cells Market, By Type:

Chimeric Antigen Receptor
T Cell Receptor
Tumor-Infiltrating Lymphocytes

Engineered T Cells Market, By Application:

Breast Cancer
Colorectal Cancer
Leukemia
Lung Cancer
Melanoma

Engineered T Cells Market, By End-User:

Cancer Research Centers
Clinics
Hospitals
Others

Engineered T Cells Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Engineered T Cells Market.

Available Customizations:

Global Engineered T Cells market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Engineered T Cells Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
- 5.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
- 5.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Product Market Map
- 5.3.1. By Type
- 5.3.2. By Application
- 5.3.3. By End-User
- 5.3.4. By Region

6. North America Engineered T Cells Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
- 6.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
- 6.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Engineered T Cells Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Application
    - 6.3.1.2.3. By End-User
- 6.3.2. Canada Engineered T Cells Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Application
    - 6.3.2.2.3. By End-User
- 6.3.3. Mexico Engineered T Cells Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Application
    - 6.3.3.2.3. By End-User

7. Europe Engineered T Cells Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
- 7.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
- 7.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Engineered T Cells Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
    - 7.3.1.2.3. By End-User
- 7.3.2. United Kingdom Engineered T Cells Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
    - 7.3.2.2.3. By End-User
- 7.3.3. France Engineered T Cells Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
    - 7.3.3.2.3. By End-User
- 7.3.4. Italy Engineered T Cells Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
    - 7.3.4.2.3. By End-User
- 7.3.5. Spain Engineered T Cells Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application
    - 7.3.5.2.3. By End-User

8. Asia-Pacific Engineered T Cells Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
- 8.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
- 8.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Engineered T Cells Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
    - 8.3.1.2.3. By End-User
- 8.3.2. Japan Engineered T Cells Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
    - 8.3.2.2.3. By End-User
- 8.3.3. India Engineered T Cells Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
    - 8.3.3.2.3. By End-User
- 8.3.4. Australia Engineered T Cells Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
    - 8.3.4.2.3. By End-User
- 8.3.5. South Korea Engineered T Cells Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By End-User

9. South America Engineered T Cells Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
- 9.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
- 9.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Engineered T Cells Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
    - 9.3.1.2.3. By End-User
- 9.3.2. Argentina Engineered T Cells Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
    - 9.3.2.2.3. By End-User
- 9.3.3. Colombia Engineered T Cells Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application
    - 9.3.3.2.3. By End-User

10. Middle East and Africa Engineered T Cells Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
- 10.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
- 10.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Engineered T Cells Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
    - 10.3.1.2.3. By End-User
- 10.3.2. Saudi Arabia Engineered T Cells Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
    - 10.3.2.2.3. By End-User
- 10.3.3. UAE Engineered T Cells Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application
    - 10.3.3.2.3. By End-User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Amgen Inc
14.2. Athenex, Inc.
14.3. Bellicum Pharmaceuticals Inc
14.4. Bristol-Myers Squibb Co
14.5. Eli Lilly & Co
14.6. Gilead Sciences Inc
14.7. Novartis AG
14.8. Oxford Biomedica PLC
14.9. Pfizer Inc
14.10. Precision BioSciences Inc